ClearPoint Neuro resumed with a Buy at B. Riley

B. Riley analyst Neil Chatterji resumed coverage of ClearPoint Neuro with a Buy rating and $14 price target. The analyst says ClearPoint offers a real-time brain targeting and guidance platform ideal for laser, cell, and gene therapy treatments of tumor and neurodegenerative diseases of the brain. The company has the ability to maintain a strong sales growth trajectory, and now is a "compelling time to take a second look given the pullback in share levels," the analyst tells investors in a research note.